Source externe
ScienceDaily – Health & Medicine
Scientists discover a hidden hereditary form of aggressive prostate cancer
Scientists have discovered a rare inherited mutation in the CDK12 gene linked to aggressive prostate cancer, with all five identified carriers developing metastatic disease between ages 44 and 62. The finding could lead to expanded genetic testing, helping families uncover…
hier· UrologieLire chez la source

Source externe
Medical Xpress – Actualités Santé
AI and nanotechnology enable five-minute drug screening from a single drop of urine
As drug-related crime rises rapidly worldwide, the need for fast, reliable technologies that can identify illicit drug use at the point of testing is becoming increasingly urgent. Laboratory testing can provide accurate results, but it requires multiple sample preparation steps…
il y a 2 jours· UrologieLire chez la source

Source externe
Medical Xpress – Actualités Santé
What men need to know after a major update to prostate cancer guidelines
Middle-aged men should undergo regular screening for prostate cancer, the American Cancer Society said Thursday in a major change to its guidelines.
le 13 nov. 2026· UrologieLire chez la source

Source externe
Medical Xpress – Actualités Santé
American Cancer Society updates prostate cancer screening guideline: Regular PSA testing for average- and high-risk men
The American Cancer Society (ACS) today released an updated guideline for prostate cancer screening to help find cancer before it spreads and reduce the risk of dying from the disease. Key changes include a direct recommendation for prostate-specific antigen (PSA)-based…
le 12 nov. 2026· UrologieLire chez la source

Source externe
Medical Xpress – Actualités Santé
New guidelines recommend regular prostate cancer screening for all middle-aged men
Experts now recommend regular prostate cancer screening for all men ages 50 to 69 and earlier for higher-risk groups, according to new American Cancer Society (ACS) guidelines.
le 12 nov. 2026· UrologieLire chez la source

Source externe
Medical Xpress – Actualités Santé
Molecular brace traps two cancer-driving proteins to suppress prostate cancer growth in preclinical tests
Many modern cancer drugs typically target a specific protein or signaling pathway to treat tumors. Now, researchers at the University of Michigan Health Rogel Cancer Center are taking a new approach by throwing a molecular wrench into the machinery driving prostate cancer. In…
le 11 nov. 2026· UrologieLire chez la source

Source externe
Medical Xpress – Actualités Santé
Prostate cancer drug combination adds toxicity without clear benefit for tumors lacking targetable mutations
The prospective, multicenter, randomized phase 2 ZZ-FIRST clinical trial, led by the Vall d'Hebron Institute of Oncology's (VHIO) Prostate Cancer Group, evaluated the androgen receptor pathway inhibitor (ARPI) enzalutamide plus the poly(ADP-ribose) polymerase inhibitor (PARPi)…
le 10 nov. 2026· UrologieLire chez la source

Source externe
Medical Xpress – Actualités Santé
Immune proteins offer new clues to how prostate cancer could be prevented
A new study led by researchers at Oxford Population Health shows that higher levels of proteins involved in activating and coordinating the immune system were associated with a lower risk of developing prostate cancer. The findings suggest that the body's ability to recognize…
le 10 nov. 2026· UrologieLire chez la source

Source externe
Medical Xpress – Actualités Santé
New study identifies biological mechanism driving therapy resistance in advanced prostate cancer
A multi-institutional collaborative study led by researchers at the University of Chicago and the Fred Hutchinson Cancer Center has identified a previously unknown biological mechanism that controls cell identity and treatment resistance in advanced prostate cancer.
le 7 nov. 2026· UrologieLire chez la source
